OPEN END TURBO LONG - GSK PLC Stock

Certificat

DE000MG5F3D4

Market Closed - Börse Stuttgart 09:30:51 2024-07-02 EDT
3.51 EUR -5.14% Intraday chart for OPEN END TURBO LONG - GSK PLC
Current month-8.59%
Date Price Change
24-07-02 3.51 -5.14%
24-07-01 3.7 -3.65%
24-06-28 3.84 +2.95%
24-06-27 3.73 -18.74%
24-06-26 4.59 -2.34%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 09:30 am

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying GSK PLC
Issuer Morgan Stanley
WKN MG5F3D
ISINDE000MG5F3D4
Date issued 2024-06-06
Strike 1,209 p
Maturity Unlimited
Parity 1 : 1
Emission price 5.32
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 5.38
Lowest since issue 3.51

Company Profile

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Sector
-
More about the company

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: GSK plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.04 GBP
Average target price
20.28 GBP
Spread / Average Target
+34.91%
Consensus